USA - NASDAQ:FTRP - CA31656R1029 - Common Stock
The current stock price of FTRP is 0.8421 USD. In the past month the price decreased by -0.93%. In the past year, price decreased by -82.38%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CVS | CVS HEALTH CORP | 12.56 | 101.01B | ||
CI | THE CIGNA GROUP | 10.75 | 80.57B | ||
LH | LABCORP HOLDINGS INC | 18.48 | 23.25B | ||
DGX | QUEST DIAGNOSTICS INC | 19.53 | 20.66B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 137.57 | 18.03B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 13.63 | 16.08B | ||
HIMS | HIMS & HERS HEALTH INC | 67.68 | 12.24B | ||
DVA | DAVITA INC | 12.91 | 8.94B | ||
GH | GUARDANT HEALTH INC | N/A | 7.89B | ||
CHE | CHEMED CORP | 19.36 | 6.31B | ||
RDNT | RADNET INC | 204.61 | 5.67B | ||
BTSG | BRIGHTSPRING HEALTH SERVICES | 40.09 | 5.26B |
Field Trip Health Ltd. engages in development and delivery of technology-enabled psychedelic therapies. The company is headquartered in Toronto, Ontario. The company went IPO on 2009-02-18. Through its Field Trip Discovery, it is engaged in developing psychedelic molecules and conducts research on plant-based psychedelics. Its Field Trip Health division operates clinics across North America and Europe providing ketamine-assisted psychotherapy (KAP) and therapies with other legal psychedelics under various programs. Its Field Trip Discovery division focuses on developing medicines targeting serotonin 5HT2A receptors. The company is conducting preclinical research into its first psychedelic molecule, FT-104, targeted for treatment resistant depression (TRD) and postpartum depression (PPD). The company is also exploring families of new chemical entity (NCE) structures, coined the FT-200 Group. Its Field Trip Digital division develops digital tools, such as the mobile application, Trip, and the patient application, Portal, to support and enhance patient outcomes and experience.
FIELD TRIP HEALTH LTD
30 Duncan Street, Suite 401
TORONTO ONTARIO CA
Employees: 0
The current stock price of FTRP is 0.8421 USD. The price increased by 1.07% in the last trading session.
The exchange symbol of FIELD TRIP HEALTH LTD is FTRP and it is listed on the Nasdaq exchange.
FTRP stock is listed on the Nasdaq exchange.
9 analysts have analysed FTRP and the average price target is 50.54 USD. This implies a price increase of 5901.43% is expected in the next year compared to the current price of 0.8421. Check the FIELD TRIP HEALTH LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FIELD TRIP HEALTH LTD (FTRP) has a market capitalization of 48.97M USD. This makes FTRP a Nano Cap stock.
FIELD TRIP HEALTH LTD (FTRP) currently has 0 employees.
FIELD TRIP HEALTH LTD (FTRP) has a support level at 0.8 and a resistance level at 0.86. Check the full technical report for a detailed analysis of FTRP support and resistance levels.
The Revenue of FIELD TRIP HEALTH LTD (FTRP) is expected to grow by 267.08% in the next year. Check the estimates tab for more information on the FTRP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FTRP does not pay a dividend.
FIELD TRIP HEALTH LTD (FTRP) will report earnings on 2022-11-14.
FIELD TRIP HEALTH LTD (FTRP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
ChartMill assigns a technical rating of 1 / 10 to FTRP. When comparing the yearly performance of all stocks, FTRP is a bad performer in the overall market: 89.45% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to FTRP. While FTRP seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months FTRP reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -15.25% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -1125.3% | ||
ROA | -53.55% | ||
ROE | N/A | ||
Debt/Equity | 0.4 |
9 analysts have analysed FTRP and the average price target is 50.54 USD. This implies a price increase of 5901.43% is expected in the next year compared to the current price of 0.8421.
For the next year, analysts expect an EPS growth of -20.59% and a revenue growth 267.08% for FTRP